Self-guided digital treatment with virtual reality for panic disorder and agoraphobia: a study protocol for a randomized controlled trial.
Agoraphobia
Cognitive behavioral therapy
E-health
Panic disorder
Self-guided help
Short-term treatment
Virtual reality
Journal
Trials
ISSN: 1745-6215
Titre abrégé: Trials
Pays: England
ID NLM: 101263253
Informations de publication
Date de publication:
21 May 2022
21 May 2022
Historique:
received:
05
02
2022
accepted:
28
04
2022
entrez:
21
5
2022
pubmed:
22
5
2022
medline:
25
5
2022
Statut:
epublish
Résumé
Cognitive behavioral therapy is the first-line treatment for patients with panic disorder (PD) and agoraphobia (AG). Yet, many patients remain untreated due to limited treatment resources. Digital self-guided short-term treatment applications may help to overcome this issue. While some therapeutic applications are already supported by health insurance companies, data on their efficacy is limited. The current study investigates the effect of self-guided digital treatment comprising psychoeducation and virtual reality exposure therapy (VRET). Thirty patients diagnosed with PD, AG, or panic disorder with agoraphobia (PDA) will be randomly assigned to either the experimental group (EG) or the control group (CG). Participants of both groups will undergo baseline diagnostics in the first two sessions. The subsequent treatment for the EG consists of a self-guided 6-week phase of application-based psychoeducation, one therapy session preparing for the VRET, and 4 weeks of application-based self-guided VRET. To control for the potential effects of the therapy session with the therapist, the CG will receive relaxation and stress-reduction training instead. All patients will then undergo a closing session which terminates with the post-assessment (~ 10 weeks after baseline assessment) and a follow-up assessment 6 weeks following the closing session. Symptom severity (primary outcome) will be assessed at baseline, interim, post-treatment, and follow-up. Additionally, remission status (secondary outcome) will be obtained at follow-up. Both measures will be compared between the groups. The current study aims at providing insights into the efficacy of short-term treatment applications including psychoeducation and self-guided VRET. If successful, this approach might be a feasible and promising way to ease the burden of PD, AG, and PDA on the public health system and contribute to a faster access to treatment. ISRCTN ISRCTN10661970 . Prospectively registered on 17 January 2022.
Sections du résumé
BACKGROUND
BACKGROUND
Cognitive behavioral therapy is the first-line treatment for patients with panic disorder (PD) and agoraphobia (AG). Yet, many patients remain untreated due to limited treatment resources. Digital self-guided short-term treatment applications may help to overcome this issue. While some therapeutic applications are already supported by health insurance companies, data on their efficacy is limited. The current study investigates the effect of self-guided digital treatment comprising psychoeducation and virtual reality exposure therapy (VRET).
METHODS
METHODS
Thirty patients diagnosed with PD, AG, or panic disorder with agoraphobia (PDA) will be randomly assigned to either the experimental group (EG) or the control group (CG). Participants of both groups will undergo baseline diagnostics in the first two sessions. The subsequent treatment for the EG consists of a self-guided 6-week phase of application-based psychoeducation, one therapy session preparing for the VRET, and 4 weeks of application-based self-guided VRET. To control for the potential effects of the therapy session with the therapist, the CG will receive relaxation and stress-reduction training instead. All patients will then undergo a closing session which terminates with the post-assessment (~ 10 weeks after baseline assessment) and a follow-up assessment 6 weeks following the closing session. Symptom severity (primary outcome) will be assessed at baseline, interim, post-treatment, and follow-up. Additionally, remission status (secondary outcome) will be obtained at follow-up. Both measures will be compared between the groups.
DISCUSSION
CONCLUSIONS
The current study aims at providing insights into the efficacy of short-term treatment applications including psychoeducation and self-guided VRET. If successful, this approach might be a feasible and promising way to ease the burden of PD, AG, and PDA on the public health system and contribute to a faster access to treatment.
TRIAL REGISTRATION
BACKGROUND
ISRCTN ISRCTN10661970 . Prospectively registered on 17 January 2022.
Identifiants
pubmed: 35597959
doi: 10.1186/s13063-022-06366-x
pii: 10.1186/s13063-022-06366-x
pmc: PMC9123669
doi:
Types de publication
Clinical Trial Protocol
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
426Subventions
Organisme : Deutsche Forschungsgemeinschaft
ID : 2493/1: 398510439
Informations de copyright
© 2022. The Author(s).
Références
Behav Res Ther. 1999 Jun;37(6):559-74
pubmed: 10372469
BMC Psychol. 2015 Aug 05;3:26
pubmed: 26246900
Arch Gen Psychiatry. 1989 Nov;46(11):984-92
pubmed: 2684086
BMJ. 2002 Sep 21;325(7365):652-4
pubmed: 12242181
J Anxiety Disord. 2019 Jan;61:18-26
pubmed: 30646997
Front Psychol. 2019 Sep 10;10:1758
pubmed: 31551840
Behav Ther. 2012 Jun;43(2):271-84
pubmed: 22440065
Eur Psychiatry. 1998;13 Suppl 2:51s-5s
pubmed: 19698673
J Anxiety Disord. 2015 Oct;35:88-102
pubmed: 26422822
Front Hum Neurosci. 2020 Mar 25;14:86
pubmed: 32269517
Int Clin Psychopharmacol. 1995 Jun;10(2):83-93
pubmed: 7673660
CNS Drugs. 2007;21(9):741-64
pubmed: 17696574
Lancet. 2006 Sep 16;368(9540):1023-32
pubmed: 16980119
Front Hum Neurosci. 2018 Sep 25;12:372
pubmed: 30319376
Health Psychol. 1997 Mar;16(2):114-22
pubmed: 9269881
Clin Psychol Rev. 2010 Feb;30(1):37-50
pubmed: 19775792
J Anxiety Disord. 2019 Jan;61:27-36
pubmed: 30287083
Curr Psychiatry Rep. 2018 May 19;20(6):44
pubmed: 29779065
Front Psychol. 2017 Oct 17;8:1841
pubmed: 29089917
Cost Eff Resour Alloc. 2019 Apr 27;17:9
pubmed: 31061640
JMIR Ment Health. 2016 Mar 01;3(1):e7
pubmed: 26932350
Dialogues Clin Neurosci. 2017 Jun;19(2):93-107
pubmed: 28867934
Depress Anxiety. 2010 Feb;27(2):113-33
pubmed: 20143426
Behav Cogn Psychother. 2014 Jul;42(4):497-501
pubmed: 23829940
Curr Psychiatry Rep. 2007 Aug;9(4):284-90
pubmed: 17880859
J Nerv Ment Dis. 1994 Feb;182(2):72-9
pubmed: 8308535
Expert Rev Neurother. 2002 May;2(3):377-83
pubmed: 19810869
Eur Neuropsychopharmacol. 2005 Aug;15(4):435-43
pubmed: 15925492
Behav Res Ther. 2002 Mar;40(3):325-41
pubmed: 11863242
J Med Internet Res. 2013 Nov 15;15(11):e247
pubmed: 24240579
BMC Psychol. 2016 Feb 10;4:8
pubmed: 26865173
Clin Epidemiol. 2017 Mar 15;9:157-166
pubmed: 28352203
J Clin Psychiatry. 2005;66 Suppl 4:28-32
pubmed: 15842185
Behav Res Methods. 2007 May;39(2):175-91
pubmed: 17695343
Br J Clin Psychol. 2006 Nov;45(Pt 4):499-514
pubmed: 17076960
Behav Res Ther. 2021 Jun;141:103858
pubmed: 33862407
PLoS One. 2013 Jul 03;8(7):e62873
pubmed: 23843932
Ann Intern Med. 2013 Feb 5;158(3):200-7
pubmed: 23295957
Psychother Psychosom Med Psychol. 2003 Sep-Oct;53(9-10):406-11
pubmed: 14528410